The Ozempic vision loss lawsuit headlines concern claims that these medicines caused NAION, a sudden loss of blood flow to the optic nerve. That nerve carries sight signals from the eye to the brain. The latest court report lists 216 pending vision-injury cases. Those are allegations, not verdicts establishing that a medicine caused someone's injury.
The practical answer is clear: sudden vision loss or rapidly worsening eyesight needs urgent medical care, even without pain. A lawsuit headline alone doesn't decide whether an existing prescription should change.
Ozempic vision loss lawsuit: what changed
As of September 30, 2026, the day this article was written, the latest court report lists 216 pending vision-injury cases. The Judicial Panel on Multidistrict Litigation report carries the date September 1, 2026.
These cases sit in MDL 3163, meaning many federal cases grouped before one judge for proceedings before trial. Judge Karen S. Marston handles them in the Eastern District of Pennsylvania. The same report lists 4,022 pending cases in the separate gastrointestinal-injury proceeding, MDL 3094. Those concern stomach and bowel injuries. The two counts describe different proceedings.
The vision cases allege harm from the medicines and inadequate warnings, among other claims. The count includes cases involving several medicines; it isn't an Ozempic-only tally or a count of confirmed drug-caused injuries.
The current court process is about examining evidence. As of September 30, 2026, the day this article was written, Case Management Order No. 12, filed July 2, directs early discovery. Discovery means exchanging records and other evidence. The order prioritizes whether the drugs can cause the injury and questions about warning adequacy and federal labeling rules. It doesn't decide those questions.
For someone considering semaglutide, the useful response is an eye-history discussion and a clear plan for new symptoms.
What this means for someone using semaglutide
The eye concern deserves attention even though a pending case doesn't establish its cause. Ozempic and Wegovy contain semaglutide, which copies GLP-1, a gut hormone involved in fullness and blood sugar.
As of September 30, 2026, the day this article was written, a newer review adds evidence, with important limits. Khani and colleagues' review in the Journal of Clinical Pharmacology, published August 18, 2026, pooled eight studies of patient records. It found roughly twice the risk with semaglutide: a pooled relative effect of 1.93, which combines risk comparisons across studies.
The authors rated the evidence low certainty. The studies differed widely, and their design cannot establish cause and effect. Among people with overweight or obesity, the finding wasn't statistically clear, meaning chance couldn't be ruled out.
A relative increase compares two groups; it doesn't mean two people out of every hundred will lose vision. Nor can a diabetes study supply an exact risk for someone using a different preparation for weight management.
Our semaglutide and vision guide explains the medical evidence in more detail. The immediate distinction is between NAION, which injures the optic nerve, and diabetic retinopathy, diabetes-related damage at the back of the eye. They are different conditions.
What the U.S. labels and eye specialists say
As of September 30, 2026, the day this article was written, the current U.S. prescribing information does not name NAION. The Ozempic injection PDF header says Revised: 05/2026. The Wegovy PDF says Revised: 06/2026. Their warnings and side-effect sections do discuss diabetic retinopathy complications. An omitted NAION warning doesn't establish zero risk.
The European Medicines Agency's June 6, 2025 announcement classifies NAION as a very rare semaglutide side effect. That category means up to 1 in 10,000 people. EMA says treatment should be stopped if NAION is confirmed.
As of September 30, 2026, the day this article was written, U.S. eye specialists have also addressed the renewed lawsuit coverage. The American Academy of Ophthalmology and North American Neuro-Ophthalmology Society statement, dated September 22, favors an individual decision with the treating clinicians, including after a NAION diagnosis. It weighs eye risk alongside the person's other health needs. It doesn't recommend routine eye exams solely to screen for NAION risk before treatment; regularly scheduled diabetic eye exams still matter.
What the headlines don't establish about Mounjaro
Mounjaro and Zepbound contain tirzepatide, a different medicine. The July 2 court order names both among the products involved. That doesn't establish identical eye risk across all these medicines.
A 2025 JAMA Network Open study by Wang and colleagues examined people with type 2 diabetes over up to two years. It found 35 NAION diagnoses among 79,699 people prescribed semaglutide or tirzepatide, versus 19 among 79,699 comparison patients: 0.04% versus 0.02%. Researchers grouped the two medicines together. Diagnosis codes could misclassify cases, and the study couldn't establish causation.
Those figures don't rank tirzepatide as a safer substitute for one particular patient. Changing medicines still requires a fresh clinical decision.
What a prescribed route makes accountable
The claims concern whether patients were harmed and adequately warned. An accountable prescription route makes the eye history, supplied product and response to symptoms explicit. It cannot remove the medicine's risks.
The useful questions are concrete: Has a prescriber reviewed previous optic-nerve injury or diabetic eye disease? Which symptoms mean urgent assessment? Who explains whether treatment needs to stop, and who coordinates with the eye specialist?
A licensed dispensing pharmacy, a label identifying the preparation and a clear clinical contact also matter. An anonymous vial sold without a prescription leaves those questions unanswered. Our guide to getting semaglutide prescribed explains that process.
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The same distinction applies to Promise's compounded tirzepatide. FDA explains that it doesn't verify compounded drugs' safety, effectiveness or quality before marketing. Compounded semaglutide explains the product distinction.
A licensed provider may still prescribe a compounded formulation when the clinical and legal conditions are met; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
What to watch next
The useful legal developments are rulings on whether the drugs can cause NAION and whether the warnings were adequate. A future case count will describe filings, while a ruling will answer a legal question. Neither supplies an individual diagnosis.
A revised U.S. label or new research could also change the clinical discussion. For an existing prescription, the next useful conversation concerns eye history, symptoms and the plan agreed with the prescriber.
Sudden vision loss or rapidly worsening eyesight needs urgent assessment now. Waiting for a routine visit or a message reply isn't an appropriate response to that symptom.
